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While no speciﬁc genetic markers are required in the diagnosis of multiple myeloma (MM), multiple genetic abnormalities
and gene signatures are used in disease prognostication and risk stratiﬁcation. This is particularly important for the adequate
identiﬁcation of the high-risk MM group, which does not beneﬁt from any of the current therapies, and novel approaches need
to be proposed. Fluorescence in situ hybridization (FISH) has been employed for establishing risk-based stratiﬁcation and still
remains the most used genetic technique in the clinical routine. The incorporation of gene expression proﬁling (GEP) in the study
of MM has shown to be a very powerful test in the patient stratiﬁcation, but its incorporation in clinical routine depends on some
technicalandlogisticresolutions.Thus,FISHstillremainsthegoldstandardtestfordetectinggenomicabnormalitiesandoutcome
discrimination in MM.
1.Background
Multiple Myeloma (MM) is a malignancy characterized by
accumulation of clonal antibody-secreting plasma cells [1].
While no speciﬁc genetic markers are used for MM diag-
nosis, multiple genetic abnormalities have been associated
with malignant transformation and disease progression [2–
5]. The identiﬁcation of genetics aberrations was greatly
improved after the implementation of analytic tools capable
to overcome the technical limitations related to low prolifer-
ation of the myeloma cell. Thus, several classiﬁcations have
been proposed based on the identiﬁcation of the genomic
changes that help to discriminate between diﬀerent genetic
groups of MM patients [3, 6–9].
Overall, MM is divided into two main genetic groups:
(1) the hyperdidploid group (H-MM), which can be deﬁned
mainly by the gain of odd chromosomes 3, 5, 7, 9, 11, 15,
19, and 21 and (2) the nonhyperdiploid group (NH-MM),
characterizedbythepresenceofchromosomaltranslocations
involving the immunoglobulin H (IgH) locus with several
chromosomal partners (4, 8, 11, 16) [10–12]. Each category
includes approximately half of cases, with a very low number
of overlapping cases.
Of interest, the dissection of the genetic landscape has
provided important genetic markers with demonstrated
clinical and disease stratiﬁcation value [5, 13–15].
2.CytogeneticPrognosticMarkers—FISH
2.1. t(4;14)(p16;q32). This translocation aﬀects the telom-
eric portion of chromosome 4p leading to the dysregulation
of two protooncogenes, FGFR3 in derivate chromosome 14
(der14) and multiple myeloma SET domain (MMSET)i n
derivative chromosome 4 (der4) [16]. The t(4;14) is seen in
15–20% of primary MM [17]. The translocation is cryptic
and detectable only by FISH or reverse transcriptase—PCR
[17].
Several groups have associated the t(4;14) with infe-
rior outcome and more aggressive disease irrespective of
the treatment modality [2, 5, 18, 19]( Table 1). It has
been suggested that this group of patients can beneﬁt
from bortezomib-based therapy [20]. However, two recent
studies showed that, although bortezomib-based therapy
shows better results than previous therapies (vincristine,
adriamycin, and dexamethasone) in patients with t(4;14),2 Genetics Research International
Table 1: Abnormalities associated with outcome in MM and
techniques used for detection.
Abnormalities Outcome Test
t(4;14)(p16;q32) Poor FISH∗
t(14;16)(q32;q23) Poor FISH
t(6;14)(p21;q32) Good? FISH
t(11;14)(q13;q32) Good/neutral FISH
Deletion 17p13 Poor FISH
Deletion 13 Poor Convenlional
cytogenetics
Chromosome 1
abnormalities Poor FISH
Hyperdiploidy Good FISH or FCM∗∗
(if not associated with deletion 17p13)
∗Fluorescence in situ hybridization (FISH). ∗∗Flow cytometry.
this translocation still has prognostic implications in a great
group of patients treated with this drug [18, 19].
2.2. t(14;16)(q32;q23) and Other MAF Translocations. The
t(14;16) is found in 5–7% of all MM cases [4, 5, 21]. The
presenceoft(14;16)hasbeenassociatedwithmoreaggressive
disease and shorter survival among the patients treated
with either conventional or high-dose chemotherapy [5, 6]
(Table 1). The prognosis of this translocation was recently
challenged by a study that suggests a neutral eﬀect in a large
series of patients [21]. Given the very low prevalence of the
MAF abnormalities, the test to detect the presence of these
translocations has not been universally incorporated in the
clinical routine.
The upregulation of CCND3 (cyclin D3), as a result
of t(6;14)(p21;q32), is identiﬁed in only 3% of MM [5]
(Table 1). Until now, there is no known clinical or prognostic
information for this translocation.
2.3. t(11;14)(q13;q32). This translocation results in the
juxtaposition of CCND1 proto-oncogene with the IgH locus
and as consequence an ectopic expression of cyclin D1 [22].
Of all MM, the t(11;14) has been described in 15% of cases
and is associated with CD20 expression, lymphoplasmacytic
morphology, hyposecretory disease, and Ig light chain usage
[22, 23].
Most studies have suggested that the presence alone of
t(11;14) may confer a favorable outcome (Table 1), but this
eﬀect is not strong enough to be statistically signiﬁcant
(probably because of small magnitude of this translocation)
[22–24].Moreover,duetoheterogeneitywithinpatientswith
t(11;14) there exists a diﬃculty in establishing a favorable
outcome for patients with this genetic aberration. For
instance, the presence of K-RAS mutations in patients with
t(11;14) is also more prevalent (50%) than in patients with
other primary IgH translocations (10%) [25]. In addition,
the presence of t(11;14) is associated with an aggressive
phenotype such as plasma cell leukemia [23]. A recent study
with a larger series of patient with t(4;14) has suggested
that the eﬀect of t(11;14) on prognosis remains neutral [24]
(Table 1).
2.4. Ploidy Status. In MM, aneuploid is frequently observed
[11, 12] and delineates the disease into two main genetic
subtypes, H-MM and NH-MM. H-MM is more common
among males, has a higher incidence of MM bone disease,
and carries a more favorable outcome [6]( Table 1). Among
patients with H-MM, 13 deletion and chromosome 1
abnormalities have not apparent prognostic signiﬁcance but
the presence of deletions of 17p13 in remains an important
prognostic factor. In addition, a study showed that most of
the prognostic value of H-MM was related to the gain of
chromosome 5 [24, 26].
2.5. Deletion of 17p. The deletion of 17p13 remains the most
important molecular prognostic factor in MM [5, 6, 20].
The deletion 17p13 is generally monoallelic and includes
TP53. The abnormality is detected in only 10% of new
diagnosis MM cases, but its prevalence increases in later
stages of the disease. Patients with 17p13 deletions often
have more aggressive and extramedullary disease (such as
plasmacytomas), center nervous system involvement, and
hypercalcemia [6, 27]. This abnormality is associated with
a shorter survival irrespective of the treatment modality,
including the novel bortezomib and IMiDs-based therapies
[5, 6, 14, 27]( Table 1).
2.6. Chromosomes 1 and 13. Chromosome 1 abnormalities
are found in almost half of MM cases [28]. There is an
enrichment of genes associated with proliferation in the
aﬀected region [8]. Although the poor prognosis value
of this abnormality has been recently demonstrated, its
incorporation into standard clinical practice has not been
implemented yet [28]( Table 1).
The deletion of chromosome 13 is found in 50% of
MM cases [4–6, 8, 29]. Although this abnormality was
originally identiﬁed as negative prognostic factor in MM,
several studies had proved the association of chromosome 13
monosomywiththet(4;14)[6,30,31].Evenintheabsenceof
this association or other high-risk markers, the chromosome
13aloneisnotapredictiveofpoorprognosiswhenidentiﬁed
by FISH (Table 1). On the other hand, its identiﬁcation by
conventional cytogenetics is a surrogate of high proliferation
and is used as a poor prognostic marker [32]( Table 1).
3. Comprehensive Genomic Tools in
MM Risk Stratiﬁcation
The advent of high-resolution genomics tools provided
a remarkable revolution in the analysis of MM and the
identiﬁcationofgenomicsignaturesabletoidentifyhigh-risk
patients and to predict patient outcome [6, 8, 33]. Several
high-resolutionavailabletestsprovideacomprehensiveanal-
ysis at the DNA (aCGH, single-nucleotide polymorphism
(SNP) arrays, and whole-genome sequencing (WGS)) and
RNA levels (gene expression proﬁling (GEP)).Genetics Research International 3
Among these technologies, the use of GEP is the most
promising risk stratiﬁcation tool in MM. The use of GEP has
been successfully implemented in MM, and several genetic
signatures have been proposed [8, 33, 34]. The most used
signatures are based on the analysis of proliferation markers
orincentrosomeindexandsuccessfullydetectedthe15–20%
of worse prognosis patients [35].
The prognostic classiﬁcation, using genetic analysis as
outcome discrimination, has been used in several cohorts
of MM treated with the conventional and high-dose
chemotherapy followed by stem cell transplant (SCT) [5,
8, 35]. Moreover, the ongoing studies involving patients
with MM are focused on the use of these genetic markers
provided by genetic changes, as predictors of outcome in
those treated with proteasome inhibitors. Although GEP is
still mainly used for research purposes, some groups have
successfully implemented its use in the routine clinical care
[35]. Other approaches such as aCGH and WGS have not
been implemented in the clinical routine yet, being used in
the research laboratory.
4. Conclusion
Genetic studies have played a crucial role in the determi-
nation of the risk-based stratiﬁcation of MM. Nowadays,
FISH and GEP are the most powerful tools for successfully
identifying disease subgroups with diﬀerent outcomes.
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